Formulation and manufacturing strategies are evolving to support nasal drug delivery’s expansion beyond traditional local and systemic therapies into CNS-targeted and psychedelic-assisted treatments.
Nasal delivery is expanding well beyond its traditional applications into systemic, CNS, and psychedelic treatments, opening new therapeutic possibilities that were previously inaccessible through conventional routes.
The therapeutic rationale for intranasal psychedelic delivery runs deeper than convenience. Understanding clinical administration models and what constitutes good outcomes from both patient and practitioner perspectives is essential for anyone developing in this space.
Formulation challenges for psychedelic compounds, including stability, potency, permeation enhancers, and dosing consistency, require a different playbook than conventional nasal products. These aren’t incremental engineering problems; they’re fundamental chemistry and physics questions.
Manufacturing and scale-up introduce another layer entirely. Device-drug combination work and manufacturing operations for high-potency and controlled substances demand facilities and expertise that most CDMOs simply don’t possess.
Aimed at CMC, formulation, and manufacturing professionals in biotech and pharma, the session covers the technical, regulatory, formulation and scale-up challenges unique to next-generation psychedelic and nasal products—including the current landscape, potent and controlled substances, psychedelic challenges, and device-drug combination manufacturing.
By ticking this box, you consent to receiving communications from Upperton related to this topic and other products or services within their portfolio